Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL INIST-CNRS

Gene Section Review

FIP1L1 (factor interacting with PAPOLA and CPSF1) Adriana Zamecnikova, Soad Al Bahar Kuwait Cancer Control Center, Department of Hematology, Laboratory of Cancer Genetics, Kuwait

Published in Atlas Database: November 2014 Online updated version : http://AtlasGeneticsOncology.org/Genes/FIP1L1ID40577ch4q12.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62487/11-2014-FIP1L1ID40577ch4q12.pdf DOI: 10.4267/2042/62487

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology

binding motif (Preker et al., 1995; Kaufmann et al., Abstract 2004). Review on FIP1L1, with data on DNA/RNA, on the Size: 4 isoforms as a result of splicing processes; the encoded and where the is implicated. larger transcript has 594 amino acids (molecular Keywords weight 66526 Da). In the second isoform (559 amino acids; 63048 Da), 9 is deleted. The third FIP1L1; factor interacting with PAPOLA and isoform is the shortest (378 amino acids; molecular CPSF1; cleavage and polyadenylation specificity weight 40835 Da) due to the of some factor complex; RNA-binding. (exon 2 and 14-18) during splicing processes. In the Identity last isoform, exons 2, 9 and 11 are deleted. Expression Other names: FIP1, Rhe, hFip1 FIP1L1 expression is present in different immunitary HGNC (Hugo): FIP1L1 cells, embrionic and fetal cells, reproductive tissues, Location: 4q12 in blood and bone marrow and others. Note Localisation Recommended name: Pre-mRNA 3'-end-processing Subcellular location: Nucleus. factor FIP1. Function DNA/RNA FIP1L1 is an important part of the eukaryotic polyadenylation apparatus that plays a key role in Description polyadenylation of mRNA precursors (pre-mRNAs) Belongs to the FIP1 family; predicted to be under the by poly(A) polymerase (PAP). FIP1L1 is an integral control of a ubiquitous promoter (Gotlib et al., component of the cleavage and polyadenylation 2004). specificity factor (CPSF) complex that is composed of CPSF1, CPSF2, CPSF3, CPSF4 and FIP1L. This Protein multisubunit complex polyadenylates the 3' end of mRNA precursors by binding to the canonical Description AAUAAA signal and to U-rich sequences of mRNA Contains a region (a 42- Fip1 motif) of precursors. The FIP1L1 protein is an important homology to Fip1 (factor interacting with PAP), a bridging factor in polyadenylation processes by yeast protein with synthetic lethal function that is providing links between RNA, poly(A) polymerase involved in polyadenylation and transcriptional and other multisubunit complexes. Contributes to processes; N-terminus contains a PAP-binding site recognition of polyadenylation signal and may and its C-terminus has an arginine-rich RNA- contribute to the differential recognition of various

Atlas Genet Cytogenet Oncol Haematol. 2015; 19(11) 650 FIP1L1 (factor interacting with PAPOLA and CPSF1) Zamecnikova A, Al Bahar S

RNAs. It also interacts with poly(A)polymerase (PAP) and CPSF160 forming a ternary complex in Implicated in vitro, suggesting that they may act together in Various cancers poly(A) site recognition and in recruitment of PAP to the RNA, thereby stimulating the otherwise Diseases associated with FIP1L1 include weakly active and nonspecific polymerase (Preker et -associated hematological malignancies, al., 1995). Stimulates poly(A) addition by binding to juvenile myelomonocytic (JMML) and U-rich elements via arginine-rich RNA binding acute promyelocytic leukemia (APL). FIP1L1 motif that lies within the C-terminus of the protein, rearrangements are associated with two distinct thus significantly contributes to CPSF-mediated leukemogenic fusion : FIP1L1-PDGFRA stimulation of PAP activity (Kaufmann et al., 2004). (platelet-derived growth factor alpha) and FIP1L1 also may act to tether poly(A) polymerase to FIP1L1-RARA (retinoic acid receptor alpha) (Figure the CPSF complex and may stabilize the association 1). Genomic breakpoints in these rearrangements are of PAP with the polyadenylation apparatus. variable, but FIP1L1 usually breaks within various Presumably act as a RNA modulator and active introns (Vandenberghe et al., 2004; Iwasaki et al., player in transformation from DNA to 2014). protein (Preker et al., 1995; Helmling et al., 2001; Kaufmann et al., 2004). Many unknown roles as the exact function of FIP1L1 is unknown.

Figure 1. Mechanisms of FIP1L1 activation in hematologic malignancies. All known chimeric FIP1L1fusion consists of the amino-terminal amino acids of FIP1L that includes the conserved FIP1 homology domain (40 amino acid Fip1 motif) and the carboxy-terminal part of the partner gene, thus the nuclear localization signal of FIP1L1 is absent in the fusion protein. To date, 2 fusions proteins of FIP1L1 are known: FIP1L1-PDGFRA and FIP1L1-RARA. While FIP1L1-PDGFRA is associated with hematologic disorders with primary eosinophilia, the FIP1L1-RARA fusion was identified in patients with JMML and APL, indicating that FIP1L1 may differentially contribute to the pathogenesis of distinct types of leukemia. In the FIP1L1-PDGFRa fusion protein, the C-terminal PDGFRA portion includes the entire kinase domain but only part of the autoinhibitory juxtamembrane region, making FIP1L1 dispensable for constitutive kinase activation that can be inhibited by administration of therapy (). FIP1 motif in FIP1L1-RARA seems to play a pivotal role in its homodimerization and repression of the retinoic acid response that is required for development of APL (adopted and modified from Gotlib et al., 2004). Abbreviations: N, N-terminal site; C, C-terminal site; TM, transmembrane domain; JM, juxtamembrane domain kinase, kinase domain; DBD, DNA binding domain; LBD, ligand binding domain; JMML, juvenile myelomonocytic leukemia; APL, acute promyelocytic leukemia.

Atlas Genet Cytogenet Oncol Haematol. 2015; 19(11) 651

FIP1L1 (factor interacting with PAPOLA and CPSF1) Zamecnikova A, Al Bahar S

FIP1L1-PDGFRA fusion in t(4;17)(q12;q21)/ FIP1L1/RARA eosinophilia-associated Disease hematological malignancies Juvenile myelomonocytic leukemia and acute Note promyelocytic leukemia. FIP1L1- PDGFRA (platelet-derived growth factor Prognosis receptor, alpha) fusion have been reported in various Unknown, as only sporadic cases have been neoplasms such as chronic eosinophilic Fusions described. Reported cases described similar ATRA leukemia, chronic neutrophilic leukemia, systemic response of FIP1L1-RARA to that of PML-RARA disease, (AML) fusions. and T-cell lymphoblastic , - all with Cytogenetics overproduction of in the blood and bone t(4;17)(q12;q21). marrow; may be found in sporadic cases of (granulocytic sarcoma) accompanied by or Hybrid/Mutated gene following AML. (Gotlib et al., 2004; Metzgeroth et In-frame fusion of 5'FIP1L1-3'RARA and 5'RARA- al., 2007; Schmitt-Graeff et al., 2014). 3'FIP1L1. In all patients the rearrangement fused the RARA Prognosis exon 3 with exon 15 (Buijs et al., 2007; Kondo et al., Excellent with the use of tyrosine kinase inhibitors 2008) or exon 13 of the FIP1L1 gene (Menezes et (imatinib). al., 2011), in a manner identical to all known RARA Cytogenetics associated APL fusions. The FIP1L1-PDGFRA is the Abnormal protein consequence of a cytogenetically invisible 832 amino acids; in-frame fusion protein composed interstitial chromosomal deletion of approximately of 428 amino-terminal amino acids of FIP1L 800 kb on band 4q12. Occasionally, (including the FIP1 homology domain) and 403 FIP1L1-PDGFRA fusions are caused by terminal carboxyl-amino acids of RARA, including chromosomal translocations such as t(1;4)(q44;q12) the DNA and ligand binding domains (Kondo et al., and t(4;10)(q12;p11). In both cases, the interstitial 2008). of the FIP1L1 portion deletion creates an in-frame fusion and as a results in multiple transcript variants similar to consequence genes between FIP1L1 and PDGFRA FIP1L1-PDGFRA distinct isoforms. are deleted. Oncogenesis Hybrid/Mutated gene FIP1L1 is a subunit of the cleavage and 5'FIP1L1-3'PDGFRA. polyadenylation specific factor (CPSF) complex that Abnormal protein is involved in 3'-end mRNA processing, therefore it The encoded FIP1L1-PDGFRA fusion protein is possible that FIP1L1/RARA may interfere with consists of the first 233 amino acids of FIP1L1 FIP1L1 function (Kaufmann et al., 2004). On the (including the Fip1 motif) and the C-terminal part of other hand, retinoic acid receptor alpha (RARA), PDGFRA, encompassing the truncated JM region also known as NR1B1 (nuclear receptor subfamily 1, and the entire kinase domain. group B, member 1) is a nuclear receptor that is Oncogenesis preferentially expressed in myeloid cells. The genomic breakpoints within FIP1L1 have been Translocations that involve the RARA gene are found to be variably distributed (introns 9-13), characteristic findings in acute promyelocytic whereas all breakpoints in PDGFRA are exclusively leukemia and several RARA partner genes have found within exon 12, which encompasses the been identified resulting in various fusion gene juxtamembrane (JM) domain that is notable for its products. In all known chimeric RARA fusions the autoinhibitory function (The interruption of the JM homodimerization ability of fusion proteins appears domain of PDGFRA is a consistent feature of to be critical for leukemic transformation as well as FIP1L1-PDGFRA fusions further underlying its for repression of retinoic acid-responsive functional significance in kinase activation (Walz et transcriptional activity. While FIP1L1 don't have the al., 2009; Iwasaki et al., 2014)). Similar to the BCR- known protein-protein interaction domain, ABL1 fusion protein in chronic myeloid leukemia, experimental studies with deletion mutants revealed FIP1L1-PDGFRA is a constitutively activated that the FIP1 motif in FIP1L1-RARA plays a role in tyrosine kinase that is causally implicated in disease homodimer formation and transcriptional repressor pathogenesis with potential evolution from chronic activity. In fact, homodimer formation was phase disease to disease progression as well as demonstrated in all sensitivity to treatments with tyrosine kinase three identified isoforms of FIP1L1-RARA, as well inhibitors such as imatinib (Cools et al., 2003; Jain as RARA-FIP1L1. In addition, FIP1L1-RARA et al., 2013). associated with either FIP1L1-RARA or FIP1L1, but

Atlas Genet Cytogenet Oncol Haematol. 2015; 19(11) 652

FIP1L1 (factor interacting with PAPOLA and CPSF1) Zamecnikova A, Al Bahar S

not with RARA, further supporting the role of the elements and stimulates poly(A) polymerase. EMBO J. FIP1L1 portion in homodimerization (Buijs et al., 2004 Feb 11;23(3):616-26 2007; Kondo et al., 2008; Iwasaki et al., 2014). The Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka FIP1L1 promoter regulated expression may underlie M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic these processes and may influence FIP1L1-RARA- leukemia. Haematologica. 2008 Sep;93(9):1414-6 mediated leukemogenesis by differential of numerous potential target genes and Menezes J, Acquadro F, Perez-Pons de la Villa C, García- Sánchez F, Álvarez S, Cigudosa JC. FIP1L1/RARA with activation of multiple signaling pathways. However, breakpoint at FIP1L1 intron 13: a variant translocation in the molecular basis for FIP1L1-RARA- mediated acute promyelocytic leukemia. Haematologica. 2011 leukemogenesis is most likely complex and still Oct;96(10):1565-6 remains to be clarified. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller References MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, a novel t(4;17)(q12;q21) in a case of juvenile Hehlmann R, Hochhaus A, Cross NC, Reiter A. Recurrent myelomonocytic leukemia. Leukemia. 2007 finding of the FIP1L1-PDGFRA fusion gene in eosinophilia- May;21(5):1104-8 associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007 Jun;21(6):1183-8 Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Preker PJ, Lingner J, Minvielle-Sebastia L, Keller W. The Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, FIP1 gene encodes a component of a yeast pre-mRNA Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, polyadenylation factor that directly interacts with poly(A) Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. polymerase. Cell. 1995 May 5;81(3):379-89 A tyrosine kinase created by fusion of the PDGFRA and Schmitt-Graeff AH, Erben P, Schwaab J, Vollmer-Kary B, FIP1L1 genes as a therapeutic target of imatinib in Metzgeroth G, Sotlar K, Horny HP, Kreipe HH, Fisch P, idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Reiter A. The FIP1L1-PDGFRA fusion gene and the KIT Mar 27;348(13):1201-14 D816V are coexisting in a small subset of Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, myeloid/lymphoid neoplasms with eosinophilia. Blood. 2014 Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine Jan 23;123(4):595-7 kinase in hypereosinophilic syndrome and chronic Vandenberghe P, Wlodarska I, Michaux L, Zachée P, eosinophilic leukemia: implications for diagnosis, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, classification, and management. Blood. 2004 Apr Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, 15;103(8):2879-91 Gilliland DG, Hagemeijer A, Marynen P. Clinical and Helmling S, Zhelkovsky A, Moore CL. Fip1 regulates the molecular features of FIP1L1-PDFGRA (+) chronic activity of Poly(A) polymerase through multiple interactions. eosinophilic . Leukemia. 2004 Apr;18(4):734-42 Mol Cell Biol. 2001 Mar;21(6):2026-37 Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh Iwasaki J, Kondo T, Darmanin S, Ibata M, Onozawa M, RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Hashimoto D, Sakamoto N, Teshima T. FIP1L1 presence in Baccarani M, Grimwade D, Preudhomme C, Apperley J, FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes Martinelli G, Saglio G, Cross NC, Reiter A. The molecular to the pathogenesis of distinct types of leukemia. Ann anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia. Hematol. 2014 Sep;93(9):1473-81 2009 Feb;23(2):271-8

Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, This article should be referenced as such: Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA Zamecnikova A, Al Bahar S. FIP1L1 (factor interacting rearrangement. Blood. 2013 Nov 7;122(19):3387-8 with PAPOLA and CPSF1). Atlas Genet Cytogenet Oncol Haematol. 2015; 19(11):650-653. Kaufmann I, Martin G, Friedlein A, Langen H, Keller W. Human Fip1 is a subunit of CPSF that binds to U-rich RNA

Atlas Genet Cytogenet Oncol Haematol. 2015; 19(11) 653